Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galectin Offers Subgroup Approach For Struggling NASH Candidate

Executive Summary

Having failed to meet its primary endpoint in consecutive Phase II studies, Galectin hopes to move GR-MD-02 forward in NASH in patients with cirrhosis who have not developed esophageal varices.

Advertisement

Related Content

Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction
Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction
Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements
Seven Clinical Trial Read-Outs Due In Q4
Galectin Hopes To Set Surrogate Endpoints For NASH Cirrhosis, Despite Trial Failure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel